Published in Diabetes on October 01, 2004
Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev (2010) 1.66
RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med (2007) 1.11
Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol Med (2010) 0.98
Regulation of RAGE for attenuating progression of diabetic vascular complications. Exp Diabetes Res (2011) 0.97
Uremic Toxicity of Advanced Glycation End Products in CKD. J Am Soc Nephrol (2015) 0.94
Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed Res Int (2014) 0.89
Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc (2013) 0.88
Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study. Metabolism (2014) 0.87
Endogenous Secretory RAGE as a Novel Biomarker for Metabolic Syndrome and Cardiovascular Diseases. Biomark Insights (2007) 0.87
Shear stress modulates RAGE-mediated inflammation in a model of diabetes-induced metabolic stress. Am J Physiol Heart Circ Physiol (2012) 0.87
Losartan protects liver against ischaemia/reperfusion injury through PPAR-γ activation and receptor for advanced glycation end-products down-regulation. Br J Pharmacol (2013) 0.86
The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis. Can J Cardiol (2006) 0.84
PPAR Agonists and Cardiovascular Disease in Diabetes. PPAR Res (2008) 0.83
Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications. J Diabetes Investig (2012) 0.81
Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol (2014) 0.79
Role of metabolic environment on nitric oxide mediated inhibition of neointimal hyperplasia in type 1 and type 2 diabetes. Nitric Oxide (2013) 0.77
CNX-013-B2, a unique pan tissue acting rexinoid, modulates several nuclear receptors and controls multiple risk factors of the metabolic syndrome without risk of hypertriglyceridemia, hepatomegaly and body weight gain in animal models. Diabetol Metab Syndr (2014) 0.76
Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension? Int J Angiol (2017) 0.75
Advanced glycation end products acutely impair ca(2+) signaling in bovine aortic endothelial cells. Front Physiol (2013) 0.75
T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol (2008) 5.44
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
EuroCMR (European Cardiovascular Magnetic Resonance) registry: results of the German pilot phase. J Am Coll Cardiol (2009) 2.23
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res (2004) 2.16
Reliability of a new algorithm for continuous cardiac output determination by pulse-contour analysis during hemodynamic instability. Crit Care Med (2002) 1.99
Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging (2009) 1.87
Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation (2003) 1.71
PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res (2002) 1.66
Marine n-3 polyunsaturated fatty acids and coronary heart disease. Part I. Background, epidemiology, animal data, effects on risk factors and safety. Thromb Res (2005) 1.62
Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol (2005) 1.60
Myocardial biopsy findings and gadolinium enhanced cardiovascular magnetic resonance in dilated cardiomyopathy. Eur J Heart Fail (2005) 1.57
Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med (2011) 1.56
Prevalence of myocardial scar in patients with cryptogenic cerebral ischemic events and patent foramen ovale. JACC Cardiovasc Imaging (2010) 1.48
Myocardial biopsy based classification and treatment in patients with dilated cardiomyopathy. Int J Cardiol (2005) 1.45
Improved in vitro biocompatibility of bicarbonate-buffered peritoneal dialysis fluid. Perit Dial Int (2006) 1.44
Changes in glycation and oxidation markers in patients starting peritoneal dialysis: a pilot study. Perit Dial Int (2006) 1.43
Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation (2005) 1.42
Impact of percutaneous device implantation for closure of patent foramen ovale on valve insufficiencies. Circulation (2009) 1.41
Results of intracoronary stem cell therapy after acute myocardial infarction. Am J Cardiol (2010) 1.40
Increased expression of TGF-beta1 and IGF-I in inflammatory stenotic lesions of hemodialysis fistulas. Kidney Int (2002) 1.39
C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro. Arterioscler Thromb Vasc Biol (2004) 1.27
Blockade of advanced glycation end-product formation restores ischemia-induced angiogenesis in diabetic mice. Proc Natl Acad Sci U S A (2003) 1.26
F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res (2003) 1.26
Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol (2003) 1.22
Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation (2003) 1.19
C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes (2004) 1.17
Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir Res (2011) 1.15
The lectin-like oxidized low-density lipoprotein receptor-1 and its soluble form: cardiovascular implications. J Atheroscler Thromb (2009) 1.15
CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling. J Clin Invest (2012) 1.11
Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J (2004) 1.10
C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res (2006) 1.08
mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. J Cell Mol Med (2007) 1.08
Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial. Arterioscler Thromb Vasc Biol (2006) 1.07
Myocardial perfusion reserve in cardiovascular magnetic resonance: Correlation to coronary microvascular dysfunction. J Cardiovasc Magn Reson (2006) 1.05
AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int (2002) 1.05
LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes. Arterioscler Thromb Vasc Biol (2006) 1.04
Current variables, definitions and endpoints of the European cardiovascular magnetic resonance registry. J Cardiovasc Magn Reson (2009) 1.02
Circulating levels of lectin-like oxidized low-density lipoprotein receptor-1 are associated with inflammatory markers. Lipids (2008) 1.00
Combined assessment of myocardial perfusion and late gadolinium enhancement in patients after percutaneous coronary intervention or bypass grafts: a multicenter study of an integrated cardiovascular magnetic resonance protocol. JACC Cardiovasc Imaging (2009) 0.99
Assessment of myocardial perfusion for detection of coronary artery stenoses by steady-state, free-precession magnetic resonance first-pass imaging. Heart (2007) 0.99
The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant (2004) 0.98
Interleukin-1beta stimulates acute phase response and C-reactive protein synthesis by inducing an NFkappaB- and C/EBPbeta-dependent autocrine interleukin-6 loop. Mol Immunol (2008) 0.98
Optimal acquisition parameters for contrast enhanced magnetic resonance imaging after chronic myocardial infarction. J Cardiovasc Magn Reson (2003) 0.97
JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood (2012) 0.95
Local excitation black blood imaging at 3T: application to the carotid artery wall. Magn Reson Med (2008) 0.94
An update on advanced glycation endproducts and atherosclerosis. Biofactors (2012) 0.93
Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. Thromb Haemost (2002) 0.91
Cardiac involvement in a female carrier of Duchenne muscular dystrophy. Int J Cardiol (2008) 0.91
Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: a cardiovascular magnetic resonance study. Eur J Radiol (2010) 0.89
Erythrocytes and platelet adhesion to endothelium are mediated by specialized molecules. Clin Hemorheol Microcirc (2004) 0.89
Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcgammaRIIa. Arterioscler Thromb Vasc Biol (2004) 0.89
Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol (2005) 0.89
Ivabradine reduces chemokine-induced CD4-positive lymphocyte migration. Mediators Inflamm (2010) 0.89
Long-term exposure to LPS enhances the rate of stimulated exocytosis and surfactant secretion in alveolar type II cells and upregulates P2Y2 receptor expression. Am J Physiol Lung Cell Mol Physiol (2008) 0.89
Whole-heart coronary vein imaging: a comparison between non-contrast-agent- and contrast-agent-enhanced visualization of the coronary venous system. Magn Reson Med (2007) 0.89
Complement and dilated cardiomyopathy: a role of sublytic terminal complement complex-induced tumor necrosis factor-alpha synthesis in cardiac myocytes. Am J Pathol (2002) 0.88
Cardiac metastasis of a gastric adenocarcinoma. Eur Heart J (2009) 0.88
Dual stack black blood carotid artery CMR at 3T: application to wall thickness visualization. J Cardiovasc Magn Reson (2009) 0.88
Protein kinase C pathway is involved in transcriptional regulation of C-reactive protein synthesis in human hepatocytes. Arterioscler Thromb Vasc Biol (2004) 0.88
Detection of erythropoietin in exhaled breath condensate of nonhypoxic subjects using a multiplex bead array. Mediators Inflamm (2006) 0.87
Proinflammatory effects of C-Peptide in different tissues. Int J Inflam (2012) 0.87
Myocardial perfusion reserve assessed by T2-prepared steady-state free precession blood oxygen level-dependent magnetic resonance imaging in comparison to fractional flow reserve. Circ Cardiovasc Imaging (2012) 0.87
Efficient transient genetic labeling of human CD34+ progenitor cells for in vivo application. Regen Med (2006) 0.87
Endothelial Lu/BCAM glycoproteins are novel ligands for red blood cell alpha4beta1 integrin: role in adhesion of sickle red blood cells to endothelial cells. Blood (2006) 0.87
Volume-targeted and whole-heart coronary magnetic resonance angiography using an intravascular contrast agent. J Magn Reson Imaging (2009) 0.86
Diagnostic performance of magnetic resonance first pass perfusion imaging is equally potent in female compared to male patients with coronary artery disease. Clin Res Cardiol (2009) 0.86
The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. FASEB J (2003) 0.86
Use of integrated FDG-PET/CT in sarcoidosis. Clin Imaging (2008) 0.86
Vascular effects of PPARgamma activators - from bench to bedside. Prog Lipid Res (2007) 0.85
Intercellular adhesion molecule-4 and CD36 are implicated in the abnormal adhesiveness of sickle cell SAD mouse erythrocytes to endothelium. Haematologica (2009) 0.85
The effect of Ginkgo biloba in isolated ischemic/reperfused rat heart: a link between vitamin E preservation and prostaglandin biosynthesis. J Cardiovasc Pharmacol (2004) 0.85
Glucagon-like peptide-1(1-37) inhibits chemokine-induced migration of human CD4-positive lymphocytes. Cell Mol Life Sci (2010) 0.85
Myocardial scar extent evaluated by cardiac magnetic resonance imaging in ICD patients: relationship to spontaneous VT during long-term follow-up. Int J Cardiovasc Imaging (2010) 0.84
Statins stimulate RGS-regulated ERK 1/2 activation in human calcified and stenotic aortic valves. Exp Mol Pathol (2008) 0.84
Telmisartan inhibits CD4-positive lymphocyte migration independent of the angiotensin type 1 receptor via peroxisome proliferator-activated receptor-gamma. Hypertension (2007) 0.83
Molecular basis of erythrocyte adhesion to endothelial cells in diseases. Clin Hemorheol Microcirc (2013) 0.83
Red blood cell adhesion in diabetes mellitus is mediated by advanced glycation end product receptor and is modulated by nitric oxide. Biorheology (2009) 0.83
Prominent role of NF-kappaB in the induction of endothelial activation by endogenous nitric oxide inhibition. Nitric Oxide (2009) 0.83
Serum starvation and growth factor receptor expression in vascular smooth muscle cells. J Vasc Res (2006) 0.83
Direct inhibitory effects of Ganciclovir on ICAM-1 expression and proliferation in human coronary vascular cells (SI/MPL-ratio: >1). Med Sci Monit (2011) 0.83
Protective role of adiponectin on endothelial dysfunction induced by AGEs: a clinical and experimental approach. Microvasc Res (2011) 0.83
Myocardial inflammation and non-ischaemic heart failure: is there a role for C-reactive protein? Basic Res Cardiol (2009) 0.83
Insulin resistance and endothelial dysfunction: a mutual relationship in cardiometabolic risk. Curr Pharm Des (2013) 0.83
C-peptide: a new mediator of atherosclerosis in diabetes. Mediators Inflamm (2012) 0.82
Magnetic resonance imaging to assess acute changes in atrial and ventricular parameters after transcatheter closure of atrial septal defects. J Magn Reson Imaging (2007) 0.81
Rapid effect of single-dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomised, placebo-controlled, double-blind study. Diab Vasc Dis Res (2010) 0.81
C-peptide promotes lesion development in a mouse model of arteriosclerosis. J Cell Mol Med (2012) 0.81
Characterization of p43(ARF), a derivative of the p43 component of multiaminoacyl-tRNA synthetase complex released during apoptosis. J Biol Chem (2007) 0.81
No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial. Can J Cardiol (2003) 0.81
Interferon beta-1b therapy in chronic viral dilated cardiomyopathy--is there a role for specific therapy? J Card Fail (2010) 0.81